Biocon subsidiary Biocon Biologics Ltd has entered into a definitive agreement with its partner Viatris Inc to acquire Viatris’ biosimilars business for $3.34 billion. Kiran Mazumdar Shaw, executive chairperson of Biocon Biologics on Monday said BBL has entered into an agreement with Viatris to acquire its biosimilars business for $3.34 billion, which would include cash of up to $2.34 billion …
Biocon Biologics Limited will offer approximately 15% stake to Serum Institute Life Sciences Private Limited at a post-money valuation of $4.9 billion in exchange for committed access to 100 million doses of vaccines per annum for 15 years, primarily from SILS’s upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio, including COVID-19 vaccines, for global markets. …
